Anticytokine autoantibodies in infectious diseases: Pathogenesis and mechanisms

The Lancet Infectious Diseases

Volumn 10, Issue 12, 2010, Pages 875-885

  Browne, Sarah K ^a   Holland, Steven M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE ANTIBODY; ERYTHROPOIETIN ANTIBODY; GAMMA INTERFERON ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; IMMUNOGLOBULIN; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 8 ANTIBODY; OSTEOPROTEGERIN ANTIBODY; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINCRISTINE;

ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNE POLYENDOCRINOPATHY SYNDROME TYPE 1; CRYPTOCOCCUS NEOFORMANS; GRAFT VERSUS HOST REACTION; HISTOPLASMA CAPSULATUM; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LUNG ALVEOLUS PROTEINOSIS; MUCOCUTANEOUS CANDIDIASIS; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NEOPLASM; NOCARDIA; OPPORTUNISTIC INFECTION; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW; RHEUMATIC DISEASE; THYMOMA;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; COLONY-STIMULATING FACTORS; COMMUNICABLE DISEASES; CYTOKINES; HUMANS;

EID: 78649402452     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70196-1     Document Type: Review

References (144)

1. Hellmich B, Csernok E, Schatz H, Gross WL, Schnabel A Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum 2002, 46:2384-2391.
2. Peichl P, Pursch E, Broll H, Lindley IJ Anti-IL-8 autoantibodies and complexes in rheumatoid arthritis: polyclonal activation in chronic synovial tissue inflammation. Rheumatol Int 1999, 18:141-145.
3. Wildbaum G, Nahir MA, Karin N Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 2003, 19:679-688.
4. Meager A, Vincent A, Newsom-Davis J, Willcox N Spontaneous neutralising antibodies to interferon-α and interleukin-12 in thymoma-associated autoimmune disease. Lancet 1997, 350:1596-1597.
5. Meager A, Wadhwa M, Dilger P, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 2003, 132:128-136.
6. Shiono H, Wong YL, Matthews I, et al. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol 2003, 15:903-913.
7. Lokshin AE, Winans M, Landsittel D, et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 2006, 102:244-251.
8. Trown PW, Kramer MJ, Dennin RA, et al. Antibodies to human leucocyte interferons in cancer patients. Lancet 1983, 1:81-84.
9. Antonelli G, Giannelli G, Currenti M, et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-α2 therapy. Clin Exp Immunol 1996, 104:384-387.
10. Antonelli G, Bagnato F, Pozzilli C, et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a. J Interferon Cytokine Res 1998, 18:345-350.
11. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002, 346:469-475.
12. Caruso A, Turano A Natural antibodies to interferon-gamma. Biotherapy 1997, 10:29-37.
13. Hansen MB, Svenson M, Diamant M, Bendtzen K Anti-interleukin-6 antibodies in normal human serum. Scand J Immunol 1991, 33:777-781.
14. Ross C, Hansen MB, Schyberg T, Berg K Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-α 2b and human IFN-γ in healthy blood donors. Clin Exp Immunol 1990, 82:57-62.
15. Tiberio L, Caruso A, Pozzi A, et al. The detection and biological activity of human antibodies to IL-2 in normal donors. Scand J Immunol 1993, 38:472-476.
16. Watanabe M, Uchida K, Nakagaki K, et al. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett 2007, 581:2017-2021.
17. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996, 334:630-633.
18. Behler CM, Terrault NA, Etzell JE, Damon LE Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report. J Med Case Reports 2009, 3:7335.
19. Eyles JL, Roberts AW, Metcalf D, Wicks IP Granulocyte colony-stimulating factor and neutrophils-forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol 2006, 2:500-510.
20. Akagawa KS, Kamoshita K, Tokunaga T Effects of granulocyte-macrophage colony-stimulating factor and colony-stimulating factor-1 on the proliferation and differentiation of murine alveolar macrophages. J Immunol 1988, 141:3383-3390.
21. Chen BD, Mueller M, Chou TH Role of granulocyte/macrophage colony-stimulating factor in the regulation of murine alveolar macrophage proliferation and differentiation. J Immunol 1988, 141:139-144.
22. Trapnell BC, Whitsett JA, Nakata K Pulmonary alveolar proteinosis. N Engl J Med 2003, 349:2527-2539.
23. Tanaka N, Watanabe J, Kitamura T, Yamada Y, Kanegasaki S, Nakata K Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. FEBS Lett 1999, 442:246-250.
24. Kitamura T, Tanaka N, Watanabe J, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999, 190:875-880.
25. Kitamura T, Uchida K, Tanaka N, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000, 162:658-662.
26. Iyonaga K, Suga M, Yamamoto T, Ichiyasu H, Miyakawa H, Ando M Elevated bronchoalveolar concentrations of MCP-1 in patients with pulmonary alveolar proteinosis. Eur Respir J 1999, 14:383-389.
27. Schoch OD, Schanz U, Koller M, et al. BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF. Thorax 2002, 57:277-280.
28. Crouch E, Persson A, Chang D Accumulation of surfactant protein D in human pulmonary alveolar proteinosis. Am J Pathol 1993, 142:241-248.
29. Honda Y, Takahashi H, Shijubo N, Kuroki Y, Akino T Surfactant protein-A concentration in bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Chest 1993, 103:496-499.
30. Fried J, Hinthorn D, Ralstin J, Gerjarusak P, Liu C Cure of brain abscess caused by Nocardia asteroides resistant to multiple antibiotics. South Med J 1988, 81:412-413.
31. Walker DA, McMahon SM Pulmonary alveolar proteinosis complicated by cerebral abscess: report of a case. J Am Osteopath Assoc 1986, 86:447-450.
32. Carlsen ET, Hill RB, Rowlands DT Nocardiosis and pulmonary alveolar proteinosis. Ann Intern Med 1964, 60:275-281.
33. Oerlemans WG, Jansen EN, Prevo RL, Eijsvogel MM Primary cerebellar nocardiosis and alveolar proteinosis. Acta Neurol Scand 1998, 97:138-141.
34. Taleghani-Far M, Barber JB, Sampson C, Harden KA Cerebral nocardiosis and alveolar proteinosis. Am Rev Respir Dis 1964, 89:561-565.
35. Clague HW, Harth M, Hellyer D, Morgan WK Septic arthritis due to Nocardia asteroides in association with pulmonary alveolar proteinosis. J Rheumatol 1982, 9:469-472.
36. Andersen BR, Ecklund RE, Kellow WF Pulmonary alveolar proteinosis with systemic nocardiosis. A case report. JAMA 1960, 174:28-31.
37. Andriole VT, Ballas M, Wilson GL The association of nocardiosis and pulmonary alveolar proteinosis. A case study. Ann Intern Med 1964, 60:266-275.
38. Burbank B, Morrione TG, Cutler SS Pulmonary alveolar proteinosis and nocardiosis. Am J Med 1960, 28:1002-1007.
39. Raich RA, Casey F, Hall WH Pulmonary and cutaneous nocardiosis. The significance of the laboratory isolation of Nocardia. Am Rev Respir Dis 1961, 83:505-509.
40. Wongthim S, Charoenlap P, Udompanich V, Punthumchinda K, Suwanagool P Pulmonary nocardiosis in Chulalongkorn Hospital. J Med Assoc Thai 1991, 74:271-277.
41. Bjorkholm B, Elgefors B Cerebellar aspergilloma. Scand J Infect Dis 1986, 18:375-378.
42. Jones CC Pulmonary alveolar proteinosis with unusual complicating infections; a report of two cases. Am J Med 1960, 29:713-722.
43. Rosen SH, Castleman B, Liebow AA Pulmonary alveolar proteinosis. N Engl J Med 1958, 258:1123-1142.
44. Sunderland WA, Campbell RA, Edwards MJ Pulmonary alveolar proteinosis and pulmonary cryptococcosis in an adolescent boy. J Pediatr 1972, 80:450-456.
45. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007, 357:1608-1619.
46. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007, 448:1058-1062.
47. Puel A, Picard C, Lorrot M, et al. Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol 2008, 180:647-654.
48. Baggiolini M, Dewald B, Moser B Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994, 55:97-179.
49. Hebert CA, Baker JB Interleukin-8: a review. Cancer Invest 1993, 11:743-750.
50. Kurdowska A, Miller EJ, Noble JM, et al. Anti-IL-8 autoantibodies in alveolar fluid from patients with the adult respiratory distress syndrome. J Immunol 1996, 157:2699-2706.
51. Kurdowska A, Noble JM, Steinberg KP, Ruzinski J, Hudson LD, Martin TR Anti-IL-8 autoantibodies in alveolar fluid from patients at risk for ARDS and with well-defined ARDS. Chest 1999, 116(suppl):9S.
52. Kurdowska A, Noble JM, Steinberg KP, Ruzinski JT, Hudson LD, Martin TR Anti-interleukin 8 autoantibody: interleukin 8 complexes in the acute respiratory distress syndrome. Relationship between the complexes and clinical disease activity. Am J Respir Crit Care Med 2001, 163:463-468.
53. Yoshikawa H, Sato K, Edahiro S, et al. Elevation of IL-12 p40 and its antibody in myasthenia gravis with thymoma. J Neuroimmunol 2006, 175:169-175.
54. de Beaucoudrey L, Puel A, Filipe-Santos O, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med 2008, 205:1543-1550.
55. H17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452:773-776.
56. Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009, 361:1760-1767.
57. Glocker EO, Hennigs A, Nabavi M, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009, 361:1727-1735.
58. Puel A, Doffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010, 207:291-297.
59. Kisand K, Wolff AS Boe, Podkrajsek KT, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010, 207:299-308.
60. Burbelo PD, Browne SK, Sampaio EP, et al. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood 2010, published online Aug 17. 10.1182/blood-2010-05-286161.
61. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006, 203:2271-2279.
62. Aujla SJ, Kolls JK IL-22: a critical mediator in mucosal host defense. J Mol Med 2009, 87:451-454.
63. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241-254.
64. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100:2610-2615.
65. Kisand K, Link M, Wolff AS, et al. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood 2008, 112:2657-2666.
66. Prummer O, Seyfarth C, Scherbaum WA, Drees N, Porzsolt F Interferon-alpha antibodies in autoimmune diseases. J Interferon Res 1989, 9(suppl 1):S67-S74.
67. Suit BE, Axelrod D, Moutsopoulos HM, Decker JL, Hooks JJ Detection of anti-interferon antibodies in systemic lupus erythematosus. Clin Exp Rheumatol 1983, 1:133-135.
68. Pozzetto B, Mogensen KE, Tovey MG, Gresser I Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J Infect Dis 1984, 150:707-713.
69. Bagnato F, Clemenzi A, Scagnolari C, et al. Neutralizing antibodies against endogenous interferon in myasthenia gravis patients. Eur Cytokine Netw 2004, 15:24-29.
70. Dorman SE, Holland SM Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 2000, 11:321-333.
71. Patel SY, Ding L, Brown MR, et al. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol 2005, 175:4769-4776.
72. Doffinger R, Helbert MR, Barcenas-Morales G, et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis 2004, 38:e10-e14.
73. Hoflich C, Sabat R, Rosseau S, et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 2004, 103:673-675.
74. Kampmann B, Hemingway C, Stephens A, et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma. J Clin Invest 2005, 115:2480-2488.
75. Tanaka Y, Hori T, Ito K, Fujita T, Ishikawa T, Uchiyama T Disseminated Mycobacterium avium complex infection in a patient with autoantibody to interferon-gamma. Intern Med 2007, 46:1005-1009.
76. Koya T, Tsubata C, Kagamu H, et al. Anti-interferon-gamma autoantibody in a patient with disseminated Mycobacterium avium complex. J Infect Chemother 2009, 15:118-122.
77. Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007, 109:1870-1877.
78. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006, 33:2398-2408.
79. Panés J, Gomollón F, Taxonera C, Hinojosa J, Clofent J, Nos P Crohn's disease: a review of current treatment with a focus on biologics. Drugs 2007, 67:2511-2537.
80. Fomsgaard A, Svenson M, Bendtzen K Auto-antibodies to tumour necrosis factor alpha in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections. Scand J Immunol 1989, 30:219-223.
81. Armitage JO Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998, 92:4491-4508.
82. Bonfield TL, Raychaudhuri B, Malur A, et al. PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. Am J Physiol Lung Cell Mol Physiol 2003, 285:L1132-L1136.
83. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001, 15:557-567.
84. Carey B, Trapnell BC The molecular basis of pulmonary alveolar proteinosis. Clin Immunol 2010, 135:223-235.
85. Ladeb S, Fleury-Feith J, Escudier E, Tran Van Nhieu J, Bernaudin JF, Cordonnier C Secondary alveolar proteinosis in cancer patients. Support Care Cancer 1996, 4:420-426.
86. Seymour JF, Presneill JJ Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002, 166:215-235.
87. Uchida K, Nakata K, Trapnell BC, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 2004, 103:1089-1098.
88. Gonzalez-Rothi RJ, Harris JO Pulmonary alveolar proteinosis. Further evaluation of abnormal alveolar macrophages. Chest 1986, 90:656-661.
89. Golde DW, Territo M, Finley TN, Cline MJ Defective lung macrophages in pulmonary alveolar proteinosis. Ann Intern Med 1976, 85:304-309.
90. Yoshida M, Ikegami M, Reed JA, Chroneos ZC, Whitsett JA GM-CSF regulates protein and lipid catabolism by alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2001, 280:L379-L386.
91. Ramirez J Pulmonary alveolar proteinosis. Treatment by massive bronchopulmonary lavage. Arch Intern Med 1967, 119:147-156.
92. Witty LA, Tapson VF, Piantadosi CA Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine (Baltimore) 1994, 73:103-109.
93. Hartung M, Salfelder K Pulmonary alveolar proteinosis and histoplasmosis: report of three cases. Virchows Arch A Pathol Anat Histol 1975, 368:281-287.
94. Uchida K, Beck DC, Yamamoto T, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007, 356:567-579.
95. Saltzman HA, Chick EW, Conant NF Nocardiosis as a complication of other diseases. Lab Invest 1962, 11:1110-1117.
96. Supena R, Karlin D, Strate R, Cramer PG Pulmonary alveolar proteinosis and Nocardia brain abscess. Report of a case. Arch Neurol 1974, 30:266-268.
97. Wolman L The cerebral complications of pulmonary alveolar proteinosis. Lancet 1961, 2:733-735.
98. Jelkmann W Molecular biology of erythropoietin. Intern Med 2004, 43:649-659.
99. Madariaga L, Amurrio C, Martin G, et al. Detection of anti-interferon-gamma autoantibodies in subjects infected by Mycobacterium tuberculosis. Int J Tuberc Lung Dis 1998, 2:62-68.
100. Chetchotisakd P, Kiertiburanakul S, Mootsikapun P, Assanasen S, Chaiwarith R, Anunnatsiri S Disseminated nontuberculous mycobacterial infection in patients who are not infected with HIV in Thailand. Clin Infect Dis 2007, 45:421-427.
101. Chetchotisakd P, Mootsikapun P, Anunnatsiri S, et al. Disseminated infection due to rapidly growing mycobacteria in immunocompetent hosts presenting with chronic lymphadenopathy: a previously unrecognized clinical entity. Clin Infect Dis 2000, 30:29-34.
102. Sungkanuparph S, Sathapatayavongs B, Pracharktam R Infections with rapidly growing mycobacteria: report of 20 cases. Int J Infect Dis 2003, 7:198-205.
103. Ding LW, Lai CC, Lee LN, Hsueh PR Disease caused by non-tuberculous mycobacteria in a university hospital in Taiwan, 1997-2003. Epidemiol Infect 2006, 134:1060-1067.
104. Lai CC, Lee LN, Ding LW, Yu CJ, Hsueh PR, Yang PC Emergence of disseminated infections due to nontuberculous mycobacteria in non-HIV-infected patients, including immunocompetent and immunocompromised patients in a university hospital in Taiwan. J Infect 2006, 53:77-84.
105. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997, 17:399-403. Finnish-German APECED Consortium.
106. Derbinski J, Schulte A, Kyewski B, Klein L Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001, 2:1032-1039.
107. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the Aire protein. Science 2002, 298:1395-1401.
108. Perheentupa J APS-I/APECED: the clinical disease and therapy. Endocrinol Metab Clin North Am 2002, 31:295-320.
109. Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 2006, 3:e289.
110. Yao Z, Spriggs MK, Derry JM, et al. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 1997, 9:794-800.
111. Vincent A, Willcox N The role of T-cells in the initiation of autoantibody responses in thymoma patients. Pathol Res Pract 1999, 195:535-540.
112. Zhang W, Liu JL, Meager A, Newsom-Davis J, Willcox N Autoantibodies to IL-12 in myasthenia gravis patients with thymoma; effects on the IFN-gamma responses of healthy CD4+ T cells. J Neuroimmunol 2003, 139:102-108.
113. Tormoehlen LM, Pascuzzi RM Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am 2008, 22:509-526.
114. Bailey RO, Dunn HG, Rubin AM, Ritaccio AL Myasthenia gravis with thymoma and pure red blood cell aplasia. Am J Clin Pathol 1988, 89:687-693.
115. Boonen A, Rennenberg R, van der Linden S Thymoma-associated systemic lupus erythematosus, exacerbating after thymectomy. A case report and review of the literature. Rheumatology (Oxford) 2000, 39:1044-1046.
116. Offerhaus GJ, Schipper ME, Lazenby AJ, et al. Graft-versus-host-like disease complicating thymoma: lack of AIRE expression as a cause of non-hereditary autoimmunity?. Immunol Lett 2007, 114:31-37.
117. Kelleher P, Misbah SA What is Good's syndrome? Immunological abnormalities in patients with thymoma. J Clin Pathol 2003, 56:12-16.
118. Tarr PE, Sneller MC, Mechanic LJ, et al. Infections in patients with immunodeficiency with thymoma (Good syndrome). Report of 5 cases and review of the literature. Medicine (Baltimore) 2001, 80:123-133.
119. Szabo G, Dolganiuc A The role of plasmacytoid dendritic cell-derived IFN alpha in antiviral immunity. Crit Rev Immunol 2008, 28:61-94.
120. Castell JV, Gomez-Lechon MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989, 242:237-239.
121. Watari K, Asano S, Shirafuji N, et al. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 1989, 73:117-122.
122. Roberts AW G-CSF: a key regulator of neutrophil production, but that's not all!. Growth Factors 2005, 23:33-41.
123. Campion G, Maddison PJ, Goulding N, et al. The Felty syndrome: a case-matched study of clinical manifestations and outcome, serologic features, and immunogenetic associations. Medicine (Baltimore) 1990, 69:69-80.
124. Ruderman M, Miller LM, Pinals RS Clinical and serologic observations on 27 patients with Felty's syndrome. Arthritis Rheum 1968, 11:377-384.
125. Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996, 88:410-416.
126. Riches PL, McRorie E, Fraser WD, Determann C, van't Hof R, Ralston SH Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N Engl J Med 2009, 361:1459-1465.
127. Kavuru MS, Sullivan EJ, Piccin R, Thomassen MJ, Stoller JK Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000, 161:1143-1148.
128. Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med 2001, 163:524-531.
129. Baerlecken N, Jacobs R, Stoll M, Schmidt RE, Witte T Recurrent, multifocal Mycobacterium avium-intercellulare infection in a patient with interferon-gamma autoantibody. Clin Infect Dis 2009, 49:e76-e78.
130. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003, 121:21-35.
131. Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009, 361:1848-1855.
132. Illa I, Diaz-Manera J, Rojas-Garcia R, et al. Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients. J Neuroimmunol 2008, 201-202:90-94.
133. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006, 355:1772-1779.
134. Borie R, Debray MP, Laine C, Aubier M, Crestani B Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur Respir J 2009, 33:1503-1506.
135. Uchida K, Nakata K, Suzuki T, et al. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 2009, 113:2547-2556.
136. Bost KL, Hahn BH, Saag MS, Shaw GM, Weigent DA, Blalock JE Individuals infected with HIV possess antibodies against IL-2. Immunology 1988, 65:611-615.
137. Bonfanti C, Caruso A, Bakhiet M, Olsson T, Turano A, Kristensson K Increased levels of antibodies to IFN-gamma in human and experimental African trypanosomiasis. Scand J Immunol 1995, 41:49-52.
138. Bhol K, Mohimen A, Ahmed AR Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 1994, 189(suppl 1):85-89.
139. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci USA 1995, 92:5239-5243.
140. de Lemos Rieper C, Galle P, Hansen MB Characterization and potential clinical applications of autoantibodies against cytokines. Cytokine Growth Factor Rev 2009, 20:61-75.
141. Courtney LP, Phelps JL, Karavodin LM An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2. Immunopharmacology 1994, 28:223-232.
142. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006, 311:1924-1927.
143. Browne SK, Holland SM Anti-cytokine autoantibodies explain some chronic mucocutaneous candidiasis. Immunol Cell Biol 2010, 88:614-615.
144. Kirkness EF, Venter JC Anti-receptor antibodies. Curr Opin Immunol 1989, 1:679-683.